<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01035320</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2004-004416-22 DMK001</org_study_id>
    <nct_id>NCT01035320</nct_id>
  </id_info>
  <brief_title>Platelet Function in Diabetic Patients With and Without Renal Impairment, and the Effects of Lipid Lowering Treatment</brief_title>
  <acronym>PLAUDIT</acronym>
  <official_title>Platelet Function in Diabetic Patients With and Without Renal Impairment, and the Effects of Lipid Lowering Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danderyd Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is compare the effects of simvastatin+ezetimibe with those of
      simvastatin alone on platelet activity, platelet-leukocyte interactions and inflammatory
      variables in diabetic patients with or without impaired renal function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A detailed study protocol is available.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the effects of simvastatin + ezetimibe with those of simvastatin alone, on thrombogenic mechanisms, in patients with diabetes mellitus type 2.</measure>
    <time_frame>6 weeks, 14-18 weeks, 22-24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare effects of simvastatin alone with those of placebo on thrombogenic mechanisms. Compare the effects of simvast. + ezetim. with those of simvast. alone on inflammatory variables. Assess how the treatment effect relate to renal function.</measure>
    <time_frame>6 weeks, 14-18 weeks, 22-24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>simvastatin + ezetimibe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cross-over study with placebo only run-in period. All patients participate in this arm with simvastatin + ezetimibe either as first treatment period (8-10 weeks)or second treatment period (8-10 weeks). The primary comparison is ezetimibe vs. placebo on top of simvastatin. A secondary comparison will be simvastatin vs. placebo run-in.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>After a placebo only run-in period patients (two groups) are treated with simvastatin + ezetimibe and simvastatin + placebo in a cross-over trial. Ezetimibe effects on top of simvastatin will be evaluated as the primary aim; simvastatin effects compared to run-in on placebo will be evaluated as a secondary aim.</description>
    <arm_group_label>simvastatin + ezetimibe</arm_group_label>
    <other_name>Simvastatin</other_name>
    <other_name>Ezetrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetes mellitus type 1 or type 2

          -  With or without established microalbuminuria (albumin-to-creatinine ratio (ACR)2,5-25
             mg/mmol for men, and 3,5-25 mg/mmol for women, according to ISH and ESC recommended
             criteria)

          -  Glomerular filtration rate (GFR) between 15-60 ml/min/1.73m2 (measured the last 6
             months) or GFR &gt;75ml/min/1.73m2. The abbreviated Modification of Diet in Renal Disease
             (MDRD) equation will be used to calculate GFR.

          -  Age 18-80 years

        Exclusion Criteria:

          -  Definite history of myocardial infarction, coronary revascularisation procedure or
             stroke. (i.e, a strong clinical indication for statin treatment)

          -  Functioning renal transplant, or living donor-related transplant planned.

          -  Patients on dialysis.

          -  Poor metabolic control, i.e HbA1c &gt; 9%

          -  Definite history of chronic liver disease, or abnormal liver function (i.e ALT &gt;1,5 x
             ULN or, if ALT not available, AST &gt; 1,5 x ULN).

          -  Evidence of active inflammatory muscle disease (e.g dermatomyositis, polymyositis), or
             CK&gt;3 x ULN;

          -  Definite previous adverse reaction to a statin or to ezetimibe

          -  Definite previous adverse reaction to acetylsalicylic acid.

          -  Definite previous adverse reaction to an ACE-inhibitor.

          -  Need for concomitant treatment with a strong inhibitor of CYP3A4, such as
             itrokonazole, ketokonazole, erythromycin, clarithromycin, HIV-protease inhibitors or
             nefazodone (i.e. agents that may markedly elevate simvastatin levels).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Hjemdahl, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Medicine, Clinical Pharmacology Unit, Karolinska University Hospital (Solna), Stockholm, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Medicine, Clinical Pharmacology Unit, Karolinska University Hospital (Solna)</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2009</study_first_submitted>
  <study_first_submitted_qc>December 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2009</study_first_posted>
  <last_update_submitted>February 25, 2011</last_update_submitted>
  <last_update_submitted_qc>February 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>Paul Hjemdahl, MD, PhD, professor</name_title>
    <organization>Clinical Pharmacology Unit, Dept of Medicine, Karolinska University Hospital/Solna</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Ezetimibe, Simvastatin Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

